The study results include chronic lymphocytic leukemia (CLL), multiple myeloma (MM), indolent NHL and MCL lymphoid malignancies.
Of the 43 abstracts, five include oral presentations, according to the company.
Two oral and three poster presentations will present summary on indolent NHL (iNHL) and MCL, comparing treatment with bendamustine-rituximab (B-R) to the standard first-line treatment, CHOP-R/CVP-R as well as another study, demonstrating enhanced quality of life with B-R in comparison to the present standards of care (CHOP-R/CVP-R) for iNHL or MCL patients.
Mundipharma Europe regional director Antony Mattessichb said the company is happy to include bendamustine data in the ASH scientific program.
"Mundipharma is committed to bringing innovative treatments to the cancer community, and we expect the impact of bendamustine-rituximab on the quality of life and outcomes of indolent non-Hodgkin lymphoma patients to remain of central interest in the future," Mattessichb added.
NHL is the tenth most common cancer across the globe and 2008 data says that there are an estimated 356,000 new cases diagnosed every year.
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world’s pharmaceutical markets.